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The continuing introduction of new treatments for varicose veins demands good information about them. Apart from clinical studies, which vary in their quality and usefulness, there have been a number of initiatives to collect data via registers, with a range of different aims. [1] [2] [3] Making a success of registers is fraught with difficulties, and they need to be well focused, adequately supported, and either mandatory or attractive for contributors. Our recent experience in debating a UK-based register for new varicose vein treatments illustrates some of the issues and may be useful in moving this agenda forward.
The challenges in evaluating and comparing new varicose vein treatments are considerable. 4 Trials now exist comparing the established methods of surgery, laser and radiofrequency ablation, and foam sclerotherapy, but many years elapsed between the widespread adoption of these methods and the generation of good comparative evidence. 5, 6 Controversy still exists about which method is most cost-effective, which works best in the long term, and which to use in individual patients.
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New devices and methods of treatment can be introduced into practice on the basis of low volume or lowquality evidence. 11 When the National Institute for Health and Care Excellence (NICE) in the UK looked at the evidence on mechanochemical ablation in 2013 12 and on cyanoacrylate glue in 2014, 13 it found the evidence on each to be inadequate for routine use without some specific measures, including audit or research and longer term follow-up. In the light of this experience and in anticipation of further new methods for treating such a common condition as varicose veins, NICE commissioned a project to examine the feasibility of data collection on all new procedures for varicose veins. NICE has a long experience in promoting successful gathering of data as new procedures come into use. But there are many difficulties, including the insufficient granularity of the national coding system for identification of new procedures, and the slow pace at which specific new codes are introduced. 14 The aims and focus of any new register are fundamental. Previous registers of varicose vein treatments, set up by the European and American Venous Forums have had very broad ambitions, to harvest information about all kinds of venous disorders and all kinds of treatments. 15, 16 The European register dwindled through poor contribution, caused at least in part by its somewhat demanding dataset. The American register has produced some interesting data but its coverage can represent only a tiny and self-selected fraction of the practitioners treating varicose veins in the USA. These observations are not intended as criticisms: they simply illustrate some of the difficulties in addressing the size of dataset, the varying enthusiasm to contribute, and the uncertainties of interpreting the outputs as reflecting either a true picture of practice overall, or a valid comparison between different treatments. Even when coverage is good (i.e. most people submit data) the main strengths of registers tend to be in providing information about safety rather than efficacy, and in supporting the data from clinical studies, rather than replacing them.
In tackling the task proposed by NICE, to collect data on new varicose vein procedures, a steering group was formed comprising seven UK vascular surgeons prominent in the field of venous disease supported by an academic centre. Clinicians were invited to sit on the steering group on the basis of experience in public and private healthcare sectors, academic record and past contribution to NICE guidance development on varicose veins. The Group's remit was to consider all aspects of developing a national register to collect data on all patients having new procedures for treatment of varicose veins. The Group's considerations were used by NICE in deciding whether to commission a register for new varicose vein procedures.
There was a range of views, and debate was animated but as a result of the discussions the following consensus emerged:
(a) A register should include only specified new procedures -both ones already in use (namely mechanochemical ablation and use of cyanoacrylate glue) and with ready capacity to add new procedures as they appear. (b) The register should be independent and not a part of the National Vascular Register, but should be designed to link with other systems, including Hospital Episodes Statistics (which records details of all hospital admissions), the Office for National Statistics mortality database, and national Patient Reported Outcome Measures (PROMs -see more below). (c) The dataset should be very small -quite unlike that which would be designed for a major controlled trial -to minimise the work of contributing, and therefore to be as inclusive as possible. Demographic data would be required to enable linkage, but only age, sex and CEAP class would contribute to analyses. There would be a minimalist record of the type of treatment and the date. It was considered that reliable capture of the most relevant adverse events should be the most important aim in the context of these new treatments. Procedural complications of greatest interest were: major allergic reaction, visual disturbance, migraine/headache and procedure aborted (with reasons). Other key safety-related outcomes such as DVT or PE would be recorded during follow-up. (d) Data on the severity of disease are relevant in documenting the reasons for treating varicose veins, and they will assist analysis and interpretation of outcome data. They will be useful to clinicians, NICE, industry and researchers in guiding future decisions about which treatments to use but risk overburdening data submission. (e) The area of greatest uncertainty and most intense discussion was about follow-up and measurement of efficacy. Opinion ranged from the point of view that all patients having new procedures must have a wide range of follow-up metrics, to the pragmatic viewpoint that many specialists treating varicose veins will not be prepared to do this. With the current pressures on the National Health Service (NHS), there can be resistance to requests for additional outpatient appointments and scans, while in private practice the incentive to submit data may be limited. NICE guidance should provide a strong steer to submit data, both in the NHS and private sector, but the demand especially for duplex scans, which might not otherwise be done, needs to be carefully considered. (f) There was agreement that a well-defined tool exists to assess each of the main aspects of effectiveness and efficacy -the Aberdeen Varicose Vein Questionnaire (AVVQ) for quality of life, and duplex ultrasound for anatomical outcome. 17 It was agreed that a single duplex scan should be required after three months (although this time interval was hotly debated). (g) How best to administer the AVVQ was a matter of concern. Currently, all patients having specified procedures; joint replacements, hernia repair, varicose vein treatments in the NHS in England are expected to complete PROMs forms before and after treatment. The varicose vein PROM tool includes the AVVQ and a recent report shows good quality of life outcomes from treating varicose veins, but there is a problem; the response rate is very poor (less than 20% for the post-treatment questionnaire). 18 Therefore, the otherwise attractive idea of establishing a link between a register of new treatments and the PROMs system risks a low response rate unless vascular specialists promote completion of forms more actively. (h) There was recognition that if the focus of a register were to be solely on safety, then it could be planned as a time-limited project. However, if long-term efficacy were to be an aim, then plans would be required for long-term funding and management. There was also recognition of the potential value of involving the medical device industry, which has information about all devices sold and which has the capacity to collect useful data -but with clear understandings about oversight and transparency. 19 The aim of this editorial has been to provoke discussion about the aims, practicality and usefulness of organised data collection on treatments for varicose veins. The idea of a wide-ranging register to capture all treatments for varicose veins is laudable but is likely to induce submission only by a self-selected cadre of enthusiasts. We see the greatest value and potential in comprehensive data collection focused on new procedures. When new procedures are introduced with a limited evidence base, regulators can reasonably expect physicians to submit safety data, and ideally some limited efficacy data, using the two well-established outcome measures of a varicose vein-specific quality of life questionnaire and duplex scanning. Agreeing datasets which are likely to promote submission requires skilful compromise between researchers and pragmatists, a very clear focus on the aim of the register, and a dataset strictly limited to achieving this goal. For new procedures, comprehensive collection of a strictly limited dataset seems substantially more useful than gathering a wide range of data from a small number of engaged practitioners.
